WFDC2 and ovarian carcinoma: And HE4, as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer, has been the first biomarker for EOC after CA125 to be approved by the U.S. Food and Drug Administration (FDA) at the year of 2008.